Longeveron (LGVN) Q2 FY26 earnings call

Longeveron is at a pivotal juncture, with the highly anticipated ELPAS-2 data readout for HLHS expected in mid-September, alongside significant external validation as an XPRIZE HealthSpan finalist for age-related frailty. The company is actively pursuing partnerships to leverage its stem cell therapy, laramester cell, across its four development programs, aiming for efficient commercialization. While advancing its pipeline, the company faces increased operating expenses and a limited cash runway, necessitating strategic financial management.